Portfolio of Single Strain Live Biotherapeutic Products (SS-LBP)

Preclinical

IND Enabling

Phase 1

Phase 2

Phase 3

ADS024 Gut-Brain Axis

Neuroinflammation

ADS024 has demonstrated pre-clinical efficacy in animal models of central neuroinflammatory disease including Multiple Sclerosis, Parkinson’s Disease, Huntington’s Disease, Amyotrophic Lateral Sclerosis, Autism and others. Adiso is pursuing studies on the selective GPCR agonism-mediated mechanism of action of ADS024 on the Gut-Brain Axis.

Publications

Featured Poster

ADS024 Attenuates Striatal Dopamine Loss and Restores Movement in Animal Models of Parkinson’s Disease

Acton S, O’Donnell MM, Periyasamy K, Dixit B, Eishingdrelo H, Hill C, Paul Ross R, Chesnel L.

LPA3 agonist-producing Bacillus velezensis ADS024 is efficacious in multiple neuroinflammatory disease models.

Brain Behav Immun. 2024 Aug 13:S0889-1591(24)00547-6.

Irwin S, Chupina Estrada A, Nelson B, Bullock A, Limketkai B, Ho W, Acton S, Chesnel L, Koon HW.

ADS024, a single-strain live biotherapeutic product of Bacillus velezensis alleviates dextran sulfate-mediated colitis in mice, protects human colonic epithelial cells against apoptosis, and maintains epithelial barrier function.

Front Microbiol. 2024 Jan 10;14:1284083.

Murphy CK, O’Donnell MM, Hegarty JW, Schulz S, Hill C, Ross RP, Rea MC, Farquhar R, Chesnel L.

Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivo.

World J Gastrointest Pathophysiol. 2023 Aug 24;14(4):71-85.

Xie Y, Chupina Estrada A, Nelson B, Feng H, Pothoulakis C, Chesnel L, Koon HW.

ADS024, a Bacillus velezensis strain, protects human colonic epithelial cells against C. difficile toxin-mediated apoptosis.

Front Microbiol. 2023 Jan 10;13:1072534.

O’Donnell MM, Hegarty JW, Healy B, Schulz S, Walsh CJ, Hill C, Ross RP, Rea MC, Farquhar R, Chesnel L.

Identification of ADS024, a newly characterized strain of Bacillus velezensis with direct Clostridiodes difficile killing and toxin degradation bio-activities.

Sci Rep. 2022 Jun 3;12(1):9283.

Acton, S., Meilin, S., Schulman, Y., Aran, J., Periyasamy, K., and L. Chesnel.

ADS024, a single strain live biotherapeutic product, attenuates MOG-EAE induced clinical symptoms in mice and zebrafish.

Multiple Sclerosis Journal Volume 29, Issue 3_suppl: MSMilan 2023 Oct 2023 P1459/415 ePoster 2023 SAGE Publications.

L. Chesnel and S. Acton (Concord, USA)

ADS024 attenuates striatal dopamine loss and restores movement in animal models of Parkinson’s disease [abstract].

Mov Disord. 2022; 37 (suppl 2).